This study is currently not recruiting participants.

Phase 2 Open-Label AC220 Monotherapy Efficacy (ACE) Study in Patients with Acute Myeloid Leukemia (AML) with FLT3-ITD Activating Mutations

Investigation of the Safety and Effectiveness of an Investigational Medication

Not Recruiting
18 years - 85 years
All
Phase N/A

Brief description of study.

The purpose of this study is to test the safety and effectiveness of the drug AC220.

Detailed description of study

The purpose of this study is to test the safety and effectiveness of the drug AC220.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Leukemia (Acute Myeloid)
  • Age: 18 years - 85 years
  • Gender: All

The purpose of this study is to investigate the safety and effectiveness of an investigational medication. This study aims to understand how the medication affects individuals and whether it is safe for use.

Participants in the study will undergo various procedures to monitor their health and the effects of the investigational medication. These procedures will help researchers gather important information about the medication's impact.

  • Who can participate: Eligibility criteria include general factors such as age range and health conditions, though specific details are not provided.
  • Study details: Participants will be required to take the investigational medication as directed and attend all scheduled appointments. They will also undergo regular health assessments to monitor their response to the medication.
Updated on 19 Feb 2024. Study ID: 1011003234 (1001-17)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team